Bronchiectasis: Phenotyping a Complex Disease

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 14, Issue , 2017, Pages S12-S18

  Chalmers, James D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

bronchiectasis; multidimensional scoring systems; phenotypes

Indexed keywords

ELASTIN; LEUKOCYTE ELASTASE;

ARTICLE; BRONCHIECTASIS; CLINICAL FEATURE; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); MICROBIOLOGY; MORBIDITY; MULTICENTER STUDY (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THORAX RADIOGRAPHY; CLUSTER ANALYSIS; COMORBIDITY; DIAGNOSTIC IMAGING; METABOLISM; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX;

BRONCHIECTASIS; CLUSTER ANALYSIS; COMORBIDITY; ELASTIN; HUMANS; INFLAMMATION; LEUKOCYTE ELASTASE; PHENOTYPE; PROGNOSIS; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX;

EID: 85015888860     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412555.2017.1286171     Document Type: Article

References (46)

1. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015; 45(5):1446−1462.
2. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010; 104(7):981–985.
3. Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013:a population-based cohort study. Eur Respir J 2016; 47(1):186−193.
4. Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany:a population-based estimation of disease prevalence. Eur Respir J 2015; 46(6):1805−1807.
5. Smith DJ. Phenotyping bronchiectasis:is it all about sputum and infection? Eur Respir J 2016; 47(4):1037−1039.
6. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113(5):1329−1334.
7. Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJ, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis:a randomised, controlled trial. Thorax 2014; 69(12):1073−1079.
8. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2):two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2(9):738−749.
9. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits:toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47(2):410−419.
10. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016; 47(5):1374−1382.
11. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes:the future of COPD. Am J Respir Crit Care Med 2010; 182(5):598−604.
12. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363(12):1128−1138.
13. Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J 2016; 47(4):1082−1092.
14. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The Bronchiectasis Severity Index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189(5):576−585.
15. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis:a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34(4):843−849.
16. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015; 12(11):1602−1611.
17. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186(7):657−665.
18. Chalmers JD, McHugh BJ, Doherty C, Smith MP, Govan JR, Kilpatrick DC, Hill AT. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis:a prospective study. Lancet Respir Med 2013; 1(3):224−232.
19. Taylor SL, Rogers GB, Chen AC, Burr LD, McGuckin MA, Serisier DJ. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann Am Thorac Soc 2015; 12(5):701−707.
20. Wells TJ, Whitters D, Sevastsyanovich YR, Heath JN, Pravin J, Goodall M, et al. Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing. J Exp Med 2014; 211(9):1893−1904.
21. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187(10):1118–1126.
22. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68(8):731–737.
23. Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European Bronchiectasis Registry:protocol for an international observational study. ERJ Open Res 2016; 2(1):pii:00081–2015. eCollection 2016.
24. Haworth CS, Johnson C, Aliberti S, Goeminne PC, Ringhausen F, Boersma W, et al. Management of bronchiectasis in Europe:data from the European bronchiectasis registry (EMBARC). Eur Respir J 2016; 48(Suppl 60):OA273. DOI:10.1183/13993003.congress-2016.OA273.
25. Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc 2015; 12(12):1764−1770.
26. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162(4 Pt 1):1277−1284.
27. Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Aetiology of bronchiectasis in Guangzhou, southern China. Respirology 2015; 20(5):739–748.
28. Aksamit TR, O'Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels ML, et al. Adult bronchiectasis patients:a first look at the United States Bronchiectasis Research Registry. Chest 2016 Nov 23; pii:S0012–3692(16)62354–1.
29. Martínez-García MÁ, de Gracia J, Relat MV, Girón RM, Carro LM, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis:the FACED score. Eur Respir J 2014; 43(5):1357−1367.
30. McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiectasis:an analysis of seven European cohorts. Thorax 2016 Aug 11; pii:thoraxjnl-2016-208481. doi:10.1136/thoraxjnl-2016-208481. [Epub ahead of print].
31. Ellis HC, Cowman S, Fernandes M, Wilson R, Loebinger MR. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores:a 19-year cohort study. Eur Respir J 2016; 47(2):482−489.
32. Rademacher J, Ringshausen FC, Suhling H, Fuge J, Marsch G, Warnecke G, et al. Lung transplantation for non-cystic fibrosis bronchiectasis. Respir Med 2016; 115:60−65.
33. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease:identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184(6):662−671.
34. Amelink M, de Nijs SB, de Groot JC, van Tilburg PM, van Spiegel PI, Krouwels FH, et al. Three phenotypes of adult-onset asthma. Allergy 2013; 68(5):674−680.
35. Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47(4):1113−1122.
36. Guan WJ, Jiang M, Gao YH, Li HM, Xu G, Zheng JP, et al. Unsupervised learning technique identifies bronchiectasis phenotypes with distinct clinical characteristics. Int J Tuberc Lung Dis 2016; 20(3):402−410.
37. Martínez-García MÁ, Vendrell M, Girón R, Máiz-Carro L, de la Rosa Carrillo D, de Gracia J, et al. The multiple faces of non-cystic fibrosis bronchiectasis. A cluster analysis approach. Ann Am Thorac Soc 2016; 13(9):1468−1475.
38. McDonnell MJ, Aliberti S, Goeminne PC, Restrepo MI, Finch S, Pesci A, et al. Comorbidities and the risk of mortality in patients with bronchiectasis:an international multicentre cohort study. Lancet Respir Med 2016; 4(12):969−979.
39. Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis:a prospective cohort analysis. Respir Med 2014; 108(2):287−296.
40. Mao B, Yang JW, Lu HW, Xu JF. Asthma and bronchiectasis exacerbation. Eur Respir J 2016; 47(6):1680−1686.
41. Navaratnam V, Millett ER, Hurst JR, Thomas SL, Smeeth L, Hubbard RB, et al. Bronchiectasis and the risk of cardiovascular disease:a population-based study. Thorax 2017; 72(2):161–166.
42. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186(7):657−665.
43. Tsang KW, Chan K, Ho P, Zheng L, Ooi GC, Ho JC, Lam W. Sputum elastase in steady-state bronchiectasis. Chest 2000; 117(2):420−426.
44. Goeminne PC, Vandooren J, Moelants EA, Decraene A, Rabaey E, Pauwels A, et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis:a case-control analysis. Respirology 2014; 19(2):203−210.
45. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2016 Dec 2. [Epub ahead of print].
46. Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis:a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J 2016; 48(3):632−647.